Close

A copper chaperone-mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis

McAlary L., Shephard V.K., Wright G.S.A., Yerbury J.J.

Preprint posted on 23 February 2021 https://www.biorxiv.org/content/10.1101/2021.02.22.432389v1

2 is better than 1: the synergistic effect of ebselen and CuATSM for ALS treatment

Selected by Utrecht Protein Folding and Assembly

Categories: biochemistry

Written by: Sanne van Falier, Laurens Geene, Janny Liebregts, and Lucas Siero

 

Background

Proteins need to fold correctly to exert their function. Misfolded proteins can lead to aggregate formation, which occurs in a variety of diseases. One such disease, amyotrophic lateral sclerosis (ALS), is a severe neurological disease which causes loss of voluntary muscle movement. Certain genetic ALS variations are associated with the misfolding of mutant forms of the protein superoxide dismutase (SOD1). SOD1 folding is stabilized through the insertion of both a Zn and Cu ion in the metal binding region (MBR). Mutations in this region (MBR mutants) lead to impeded ion insertion and enzymatic activity. Correct SOD1 folding also relies on the formation of a disulfide bridge between Cys57-Cys146, and aberrant folding without the disulfide bridge inhibits the dimerization of SOD1 needed for full enzymatic function. Wild-type like (WTL) mutants still show enzymatic activity, but make SOD1 more prone to aggregation.

Normally, the CCS chaperone facilitates copper insertion and disulfide bond formation, but it is unable to fully do so in mutated SOD1. In this preprint, the authors test two small molecules to recapitulate CCS function in a combination treatment: CuATSM, a drug already in clinical trials which facilitates copper ion insertion into SOD1 [1], and ebselen, which promotes the formation of the Cys57-Cys146 disulfide bridge [2]. While both drugs are known to independently rescue disease related phenotypes in mice [1,2], it is yet unknown whether they can be applied in a synergistic way for ALS treatment.

 

Results

To be able to study the effect of ebselen on SOD1 aggregation, the authors express EGFP-tagged SOD1 in NSC-34 motor neuron-like cells, resulting in the formation of observable inclusions. To identify cells containing inclusions, the authors optimize an analytical pipeline using CellProfiller software. With the use of machine learning, they find optimal parameters to detect inclusions at an extremely high accuracy.

Using this pipeline, they test the effect of ebselen on the inclusion formation of multiple SOD1 mutants, including WTL (A4V) and MBR (G85R) mutants. Treatment with ebselen significantly reduces the formation of inclusions, likely by facilitating the formation of the disulfide bridge. To confirm this, they test the effect of ebselen on a number of mutants including G127X, which deletes residues 127-153. This region contains Cys146 involved in the formation of the disulfide bond. Ebselen has no effect on preventing inclusion formation of SOD1 G127X, but does have a dose dependent effect on other mutants, which can form the disulfide bridge. This finding supports the notion that ebselen facilitates the formation of the disulfide bridge.

Since ebselen cannot take over the copper insertion function, a second small molecule is needed to perform this action. In previous research, CuATSM was found to be capable of delivering copper to SOD1 in cells as well as in mice [1].  A checkerboard analysis using both molecules and WT SOD1 and WTL and MBR mutants shows that the WTL mutant responds to the polytherapy, while the MBR mutant only responds to the ebselen monotherapy. The addition of ebselen decreases the required CuATSM concentration for A4V by a factor 3, while the addition of CuATSM decreases the required amount of ebselen by a factor 10. These results indicate a synergetic drug interaction.

Figure 3 a-b from McAlary et al. shows the synergistic effect of ebselen and CuATSM on specific SOD1 mutations. A4V is positively affected by combination therapy, while G85R folding is only improved by ebselen. Panel B shows that this also translates into increased survival time compared to wild-type. Figure made available under a CC-BY-NC-ND 4.0 International license.

 

Native SOD1 is active as a dimer. Mutations in the SOD1 gene can negatively affect dimerization and therefore decrease enzymatic activity even further. Treatment with ebselen, CuATSM or the combination therapy rescues this phenotype by increasing dimerization, most prominently for the G93A mutant (a WTL mutation). Furthermore, all mutants show an increase in enzymatic activity after treatment with CuATSM or the combination therapy, but not with ebselen on its own. Polytherapy has the strongest effect for V148G, rescuing the enzymatic activity more than either drug separately.

Altogether, the authors conclude that CuATSM and ebselen can both be used to support correct folding of SOD1 by acting as a CCS mimetic, promoting copper binding and disulfide formation, respectively. The combination of these two drugs can function in a synergistic way for certain SOD1 mutants, which can be exploited for personalised medicine by mutation-specific treatment.

 

Why we chose this preprint

ALS is a terrible disease with no current treatment. It is important to find therapies that can combat specific ALS mutations, and the application of multidrug therapy can contribute to this. Combination therapy is commonly used in the treatment of cancer, but has never been exploited for ALS. The polydrug therapy tested in this preprint is especially interesting because for certain mutations it not only prevents aggregation, but also partly restores the enzymatic activity of SOD1.

We are also amazed by the accuracy of the optimized machine learning algorithm. By finding the right parameters, this algorithm can be used to screen a large number of cells for the presence of inclusions, which can be applied to find further drugs able to combat ALS and other diseases associated with inclusion formation.

 

Questions to the authors

Since ebselen was originally designed for hearing loss and therefore aimed at a different target protein, would it be possible to modify the drug making it even more specific for SOD1?

Previous research into ebselen showed it to be less potent at facilitating SOD1 maturation, while a much higher concentration was used (200 µM) [2]. How do you think this is possible?

 

References

1) Roberts BR, Lim NKH, McAllum EJ, Donnelly PS, Hare DJ, Doble PA, et al. Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience. 2014. pp. 8021–8031. doi:10.1523/jneurosci.4196-13.2014

2) Capper MJ, Wright GSA, Barbieri L, Luchinat E, Mercatelli E, McAlary L, et al. The cysteine reactive small molecule ebselen facilitates effective SOD1 maturation. Nat Commun. 2018;9: 1693.

Tags: als, cuatsm, ebselen, protein aggregation, sod1

Posted on: 9 April 2021

doi: Pending

Read preprint (No Ratings Yet)

Author's response

Luke McAlary shared

Since ebselen was originally designed for hearing loss and therefore aimed at a different target protein, would it be possible to modify the drug making it even more specific for SOD1?

The major issue facing those who are attempting to develop disease-associated protein-specific therapies for protein misfolding disorders is that the targets often inhabit an ensemble of dynamic conformations in disease. How does one create compound that drugs a protein with no or only transiently populated binding pockets? Therefore, the generation of conformationally specific compounds to stabilize a misfolded protein is a non-trivial task. Given that ebselen promotes the disulphide formation of numerous disease-associated forms of SOD1, we believe that non-specificity may be useful in making the compound broadly effective for those suffering from SOD1-associated amyotrophic lateral sclerosis. We also think that monotherapy approaches to neurodegenerative disease are one reason why translation from the bench to the bedside is failing, and that potential treatments may include various compounds that all exert minimal effects by themselves, but collaborate to exert additive or synergistic effects.

 

Previous research into ebselen showed it to be less potent at facilitating SOD1 maturation, while a much higher concentration was used (200 µM) [2]. How do you think this is possible?

Research carried out previously by Capper and colleagues [2] did utilise a final concentration of ebselen at 200 µM on HEK-293 cells. This work did not attempt to determine an effective dose of ebselen, rather it was attempting to address if ebselen worked or not. In this current work here, we specifically set out to determine if the concentration of ebselen could be lowered beyond that previously reported and, most importantly, if the combination of ebselen with CuATSM could lower the effective dose of both compounds. We would hypothesize that potential differences in the redox capacities of HEK-293 and NSC-34 cells could contribute to lower/higher ebselen effectiveness in these models. What is important now is that we move towards preclinical models to assess dosages in vivo.

Have your say

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sign up to customise the site to your preferences and to receive alerts

Register here

preLists in the biochemistry category:

20th “Genetics Workshops in Hungary”, Szeged (25th, September)

In this annual conference, Hungarian geneticists, biochemists and biotechnologists presented their works. Link: http://group.szbk.u-szeged.hu/minikonf/archive/prg2021.pdf

 



List by Nándor Lipták

Fibroblasts

The advances in fibroblast biology preList explores the recent discoveries and preprints of the fibroblast world. Get ready to immerse yourself with this list created for fibroblasts aficionados and lovers, and beyond. Here, my goal is to include preprints of fibroblast biology, heterogeneity, fate, extracellular matrix, behavior, topography, single-cell atlases, spatial transcriptomics, and their matrix!

 



List by Osvaldo Contreras

ASCB EMBO Annual Meeting 2019

A collection of preprints presented at the 2019 ASCB EMBO Meeting in Washington, DC (December 7-11)

 



List by Madhuja Samaddar et al.

EMBL Seeing is Believing – Imaging the Molecular Processes of Life

Preprints discussed at the 2019 edition of Seeing is Believing, at EMBL Heidelberg from the 9th-12th October 2019

 



List by Dey Lab

Cellular metabolism

A curated list of preprints related to cellular metabolism at Biorxiv by Pablo Ranea Robles from the Prelights community. Special interest on lipid metabolism, peroxisomes and mitochondria.

 



List by Pablo Ranea Robles

MitoList

This list of preprints is focused on work expanding our knowledge on mitochondria in any organism, tissue or cell type, from the normal biology to the pathology.

 



List by Sandra Franco Iborra
Close